Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls.
HIV
cytomegalovirus
epithelial gut damage
inflammation
microbial translocation
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
12 09 2020
12 09 2020
Historique:
received:
06
08
2019
accepted:
07
10
2019
pubmed:
15
10
2019
medline:
28
4
2021
entrez:
15
10
2019
Statut:
ppublish
Résumé
Cytomegalovirus (CMV) seropositivity and anti-CMV immunoglobulin G (IgG) levels are associated with adverse health outcomes in elderly populations. Among people living with human immunodeficiency virus (PLWH), CMV seropositivity has been associated with persistent CD8 T-cell elevation and increased risk of developing non-AIDS comorbidities despite long-term antiretroviral therapy (ART). Herein, we investigated whether CMV seropositivity and elevation of anti-CMV IgG levels were associated with increased epithelial gut damage, microbial translocation, and systemic inflammation. A total of 150 PLWH (79 ART-naive and 71 ART-treated) were compared to 26 without human immunodeficiency virus (HIV) infection (uninfected controls). Plasma markers of HIV disease progression, epithelial gut damage, microbial translocation, nonspecific B-cell activation, anti-CMV and anti-Epstein-Barr virus (EBV) IgG levels, and proinflammatory cytokines were measured. CMV seropositivity and elevated anti-CMV IgG levels were associated with markers of epithelial gut damage, microbial translocation, and inflammation in PLWH and participants without HIV infection. In contrast, total nonspecific IgG, immunoglobulin M, immunoglobulin A, and anti-EBV IgG levels were not associated with these markers. CMV seropositivity was associated with markers of epithelial gut damage, microbial translocation, and inflammation independent of sociodemographic and behavioral characteristics of the study population. CMV-seropositive people with and without HIV had increased epithelial gut damage, microbial translocation, and inflammation. Furthermore, anti-CMV IgG levels were independently associated with increased epithelial gut damage and microbial translocation. CMV coinfection may partially explain persistent gut damage, microbial translocation, and inflammation in ART-treated PLWH.
Sections du résumé
BACKGROUND
Cytomegalovirus (CMV) seropositivity and anti-CMV immunoglobulin G (IgG) levels are associated with adverse health outcomes in elderly populations. Among people living with human immunodeficiency virus (PLWH), CMV seropositivity has been associated with persistent CD8 T-cell elevation and increased risk of developing non-AIDS comorbidities despite long-term antiretroviral therapy (ART). Herein, we investigated whether CMV seropositivity and elevation of anti-CMV IgG levels were associated with increased epithelial gut damage, microbial translocation, and systemic inflammation.
METHODS
A total of 150 PLWH (79 ART-naive and 71 ART-treated) were compared to 26 without human immunodeficiency virus (HIV) infection (uninfected controls). Plasma markers of HIV disease progression, epithelial gut damage, microbial translocation, nonspecific B-cell activation, anti-CMV and anti-Epstein-Barr virus (EBV) IgG levels, and proinflammatory cytokines were measured.
RESULTS
CMV seropositivity and elevated anti-CMV IgG levels were associated with markers of epithelial gut damage, microbial translocation, and inflammation in PLWH and participants without HIV infection. In contrast, total nonspecific IgG, immunoglobulin M, immunoglobulin A, and anti-EBV IgG levels were not associated with these markers. CMV seropositivity was associated with markers of epithelial gut damage, microbial translocation, and inflammation independent of sociodemographic and behavioral characteristics of the study population.
CONCLUSIONS
CMV-seropositive people with and without HIV had increased epithelial gut damage, microbial translocation, and inflammation. Furthermore, anti-CMV IgG levels were independently associated with increased epithelial gut damage and microbial translocation. CMV coinfection may partially explain persistent gut damage, microbial translocation, and inflammation in ART-treated PLWH.
Identifiants
pubmed: 31608409
pii: 5586739
doi: 10.1093/cid/ciz1001
pmc: PMC7486843
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1438-1446Subventions
Organisme : CIHR
ID : MOP 103230
Pays : Canada
Organisme : CIHR
ID : PTJ 166049
Pays : Canada
Organisme : CIHR
ID : CTN257
Pays : Canada
Organisme : CIHR
ID : HB2-164064
Pays : Canada
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
J Int AIDS Soc. 2016 Mar 03;19(1):20697
pubmed: 26945343
PLoS Pathog. 2017 Feb 27;13(2):e1006202
pubmed: 28241080
Viruses. 2018 Aug 20;10(8):
pubmed: 30127257
J Infect Dis. 2017 Sep 15;216(6):651-661
pubmed: 28934432
Medicine (Baltimore). 2016 Mar;95(11):e3162
pubmed: 26986173
Nat Rev Immunol. 2016 Jun;16(6):367-77
pubmed: 27108521
J Infect Dis. 2016 Oct 1;214 Suppl 2:S67-74
pubmed: 27625433
J Infect Dis. 2015 Jan 15;211(2):178-86
pubmed: 25081936
Clin Infect Dis. 2016 Feb 1;62(3):392-6
pubmed: 26400999
Immunol Rev. 2013 Jul;254(1):78-101
pubmed: 23772616
Front Endocrinol (Lausanne). 2019 Jul 12;10:471
pubmed: 31354634
Blood. 2015 Aug 6;126(6):746-56
pubmed: 26065651
Ann Transl Med. 2017 Nov;5(21):434
pubmed: 29201886
Clin Infect Dis. 2019 Aug 1;69(4):676-686
pubmed: 30418519
Gastroenterol Res Pract. 2019 Mar 7;2019:6156581
pubmed: 30984257
J Int AIDS Soc. 2018 Feb;21(2):
pubmed: 29412520
J Virol Methods. 2015 Dec 1;225:1-3
pubmed: 26341060
J Infect Dis. 2017 Apr 15;215(8):1212-1220
pubmed: 28199648
AIDS. 2014 Sep 10;28(14):2045-9
pubmed: 25265072
Immun Ageing. 2016 Jan 05;13:1
pubmed: 26734066
Rev Med Virol. 2019 May;29(3):e2034
pubmed: 30706584
J Infect Dis. 2014 Oct 15;210(8):1228-38
pubmed: 24755434
PLoS One. 2016 Nov 8;11(11):e0165774
pubmed: 27824907
J Infect Dis. 2011 May 15;203(10):1474-83
pubmed: 21502083
J Infect Dis. 2012 Jun 15;205(12):1788-96
pubmed: 22492856
J Infect Dis. 2014 Feb 1;209(3):452-6
pubmed: 23964106
BMC Infect Dis. 2017 Sep 11;17(1):611
pubmed: 28893184
PLoS One. 2015 Feb 03;10(2):e0117039
pubmed: 25647167
Mucosal Immunol. 2018 Sep;11(5):1429-1440
pubmed: 29907866
Drugs. 2016 Apr;76(5):533-49
pubmed: 26915027
AIDS. 2017 Sep 24;31(15):2059-2067
pubmed: 28906277
Front Immunol. 2019 Feb 21;10:289
pubmed: 30846990
Open Forum Infect Dis. 2018 Nov 05;5(11):ofy288
pubmed: 30515430
Clin Infect Dis. 2018 Aug 16;67(5):770-777
pubmed: 29506084
J Int AIDS Soc. 2015 Jun 29;18:20052
pubmed: 26130226
Transplantation. 2018 Jun;102(6):900-931
pubmed: 29596116